Home > Learning > APS > Labs

Module 1 of 3 • 5 min • Lab Interpretation

Decoding the Labs

“The Three Fraud Departments”

Your bloodstream is a 24/7 financial network — trillions of transactions every second. Platelets are the security team. The coagulation cascade is the bank’s fraud detection system — a layered network of checkpoints designed to stop unauthorized withdrawals (bleeding).

Now the fraud detection system goes rogue. It flags legitimate transactions as suspicious. Accounts freeze. Money stops flowing to critical branches. That’s Antiphospholipid Syndrome — and the rogue detectors are the aPL antibodies. You can’t fix the system until you know which departments went rogue — and how to prove it.

The Three Fraud Departments

1

Lupus Anticoagulant (LA) — The Transaction Speed Monitor

The most important detector — and the most paradoxical.

This department monitors how fast transactions process. Here’s the great paradox: in the test tube (in vitro), LA SLOWS coagulation — hence “anticoagulant.” But in the body (in vivo), it PROMOTES thrombosis. The monitor that slows things down during the audit causes real accounts to lock up in real time.

“LA: Liar in the Lab, Assassin in the Artery” — In vitro anticoagulant. In vivo procoagulant.

The 3-Step Detection

1
Screen: aPTT is prolonged — a Part-Time Teller works the window, so transactions drag.
2
Mixing Study: Add normal plasma. Normalizes? Mix and Fix — the Factor was missed (deficiency). Still slow? Mix and Miss — an Inhibitor exists.
3
Confirmatory: Flood with excess phospholipid. Normalizes? LA confirmed — the problem was phospholipid-dependent.
“Mix and Fix — the Factor was missed. Mix and Miss — an Inhibitor exists.”
Two Practical Consequences

1. Cannot test on anticoagulation — the drugs also slow transactions, making results uninterpretable. Test before starting, or use aCL/anti-β2GPI instead.

2. Falsely elevates the INR — LA interferes with the PT assay (also phospholipid-dependent), so the reported INR doesn’t reflect true anticoagulation intensity. Use a chromogenic factor X assay instead to monitor warfarin in LA-positive patients.

“LA: Liar in the Lab, Liar on the INR — Factor X tells the truth”
2

Anticardiolipin (aCL) — The Card Department

Doesn’t time transactions — flags the cards themselves.

Instead of monitoring transaction speed, this department scans the cards — antibodies targeting cardiolipin (a phospholipid in cell membranes). Because it reads the card directly rather than timing transactions, it CAN run while anticoagulation is active — a key practical difference from LA. But a card is only plastic: the antibody actually works through β2GPI, which is why the Card leads you to the PI (Department 3).

“aCL = the CARD; the PI (β2GPI) owns the real account” — antiCARDiolipin is the plastic; the antibody binds through β2GPI, so the PI (anti-β2GPI, especially Domain I) names the true culprit — more specific.
  • Method: ELISA — measures antibodies directly, not clotting function
  • 2023 thresholds: IgG ≥40 GPL units or IgM ≥80 MPL units for highest-weight category
  • ✓ Can test on anticoagulation
  • Limitation: Less specific — infections and medications can cause transient false positives (a cloned card)
3

Anti-β2GPI — The Identity Investigator

Tracks the actual ringleader — not just the paperwork trail.

While the Card Department reads the plastic, the Identity Investigator tracks the actual person responsible. β2-Glycoprotein I is the cofactor aPL antibodies need to bind phospholipids — it’s the true antigenic target. Finding antibodies against it is like confirming the ringleader’s exact address.

  • Method: ELISA targeting anti-β2GPI
  • Most specific antibody for true APS pathogenesis
  • Domain I antibodies are the 2023 gold standard — the ringleader’s office, not just the neighborhood
  • ✓ Can test on anticoagulation
“B2G-PI = Private Investigator” — The PI tracks down the actual ringleader directly, not just the paperwork trail. Most specific because it targets the true antigenic culprit.

Side by Side

FeatureLA (Speed Monitor)aCL (Card Dept)Anti-β2GPI (Investigator)
MethodFunctional (coag assay)ELISAELISA
On anticoagulation?❌ Cannot test✓ Can test✓ Can test
Specificity for APSHighestModerateHigh
Thrombosis predictionStrongestModerateStrong
2023 key thresholdPositive / NegativeIgG ≥40, IgM ≥80Domain I positivity

Triple Positivity

When all three departments flag the same culprit — Speed Monitor, Card Department, and Identity Investigator all positive — the case is airtight. That’s triple positivity: the grand slam of aPL profiling. These patients face the highest thrombotic risk: 5–10% per year and absolutely cannot use DOACs (see Module 3, TRAPS trial). Warfarin only.

The 12-Week Confirmation Rule

The bank doesn’t act on a single report. Transient infections can trigger temporary aPL positivity — a false alarm. The 2023 criteria require confirmation at least 12 weeks apart: two independent investigations, same conclusion. A single positive is never enough to diagnose APS.

Understanding the Coagulation Cascade

The aPL antibodies don’t attack the blood directly — they hijack the coagulation cascade, the system that normally stops bleeding after injury. Understanding how it works explains why LA prolongs the PTT but not the PT, why certain factor deficiencies look different from lupus anticoagulant in the lab, and how our anticoagulants target different parts of this pathway.

PTT — Regular Lane
Intrinsic Pathway
PT — Express Lane
Extrinsic Pathway
↳ XII activates cascade — isolated XII deficiency does not cause bleeding
12
Factor XII
Contact activation — isolated XII deficiency ≠ bleeding
↓
11
Factor XI
Hemophilia C
↓
9
Factor IX
Hemophilia B (Christmas disease)
⚠ LA interferes here (phospholipid-dependent step)
↓
8
Factor VIII
Hemophilia A — cofactor for IX
Counts down: 12 → 11 → 9 → 8
Heparin → PTT
“The other one is the other one.” — Dr. Goljan
III
Tissue Factor (III)
Exposed on vessel injury
↓
7
Factor VII
Activates X (with TF)
“Seven stands alone”
PT↑ + PTT normal = Factor VII only
Going to WAR with your EX over the ProperTy
WAR = Warfarin • EX = Extrinsic • PT = ProperTy
→ tracked by PT / INR
Vitamin K–dependent: II, VII, IX, X + Protein C & S
Common Pathway
Both lanes merge here
↓
Factor X + V
Prothrombinase complex
↓
Prothrombin (Factor II)
→ Thrombin: the final turnstile
↓
Fibrinogen → Fibrin 🔒
Crosslinked and stabilized by Factor XIII
Pearl: “LA lies low — half the time PTT won’t show”
(LA falsely normal in ~50% of cases)
Regular Lane counts down — twelve, eleven, nine, eight.
Express Lane has one stop — Factor Seven, no wait.
Both lines end at prothrombin — it seals every fate.

Test Yourself

Q1: A 32-year-old woman with recurrent DVTs has a prolonged aPTT. Mixing study does NOT correct. Next step?

Show Answer

Q3: Which aPL profile carries the highest thrombotic risk, and what therapy does it mandate?

Show Answer

Summary

  • Three aPL antibodies: LA (functional assay), aCL (ELISA), anti-β2GPI (ELISA)
  • LA: in vitro anticoagulant, in vivo procoagulant — strongest thrombosis predictor
  • LA cannot be tested on anticoagulation; aCL and anti-β2GPI can
  • Mix and Fix — the Factor was missed; Mix and Miss — an Inhibitor exists (LA)
  • LA lies on the INR — use chromogenic factor X assay for warfarin monitoring
  • The Card leads to the PI — aCL binds via β2GPI; anti-β2GPI (Domain I) is the most specific target
  • Triple positivity = grand slam = highest risk (5–10%/year) = warfarin only
  • Always confirm at ≥12 weeks — never diagnose APS on a single positive test
← Back to APS OverviewNext: Clinical Manifestations →